Davenport & Co
VRTX icon

Davenport & Co’s Vertex Pharmaceuticals VRTX Stock Holding History

Davenport & Co’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$106M Sell
202,800
-4,308
-2% -$2.21M 0.53% 56
2026
Q2 		$103M Sell
207,108
-3,044
-1% -$1.35M 0.51% 59
2026
Q1 		$93.7M Sell
210,152
-1,425
-0.7% -$664K 0.51% 67
2025
Q4 		$95.9M Sell
211,577
-5,707
-3% -$2.46M 0.51% 64
2025
Q3 		$85.3M Sell
217,284
-8,900
-4% -$3.72M 0.45% 75
2025
Q2 		$100M Buy
226,184
+874
+0.4% +$403K 0.55% 61
2025
Q1 		$110M Buy
225,310
+7,242
+3% +$3.37M 0.64% 50
2024
Q4 		$87.6M Sell
218,068
-1,641
-0.7% -$761K 0.5% 71
2024
Q3 		$102M Sell
219,709
-1,816
-0.8% -$872K 0.58% 58
2024
Q2 		$104M Buy
221,525
+2,734
+1% +$1.19M 0.63% 47
2024
Q1 		$91.3M Sell
218,791
-447
-0.2% -$189K 0.56% 59
2023
Q4 		$89.3M Buy
219,238
+103,769
+90% +$38.3M 0.61% 57
2023
Q3 		$40.3M Sell
115,469
-442
-0.4% -$155K 0.3% 99
2023
Q2 		$40.7M Buy
115,911
+101,567
+708% +$34.2M 0.3% 97
2023
Q1 		$4.52M Sell
14,344
-394
-3% -$118K 0.04% 281
2022
Q4 		$4.26M Buy
14,738
+157
+1% +$47.8K 0.03% 272
2022
Q3 		$4.22M Sell
14,581
-6,284
-30% -$1.81M 0.04% 263
2022
Q2 		$5.88M Sell
20,865
-1,405
-6% -$376K 0.05% 222
2022
Q1 		$5.81M Buy
22,270
+1,553
+7% +$369K 0.04% 245
2021
Q4 		$4.55M Buy
20,717
+2,318
+13% +$451K 0.03% 275
2021
Q3 		$3.34M Buy
18,399
+1,272
+7% +$248K 0.02% 302
2021
Q2 		$3.45M Sell
17,127
-124,507
-88% -$26M 0.03% 262
2021
Q1 		$30.4M Buy
141,634
+8,598
+6% +$1.89M 0.29% 94
2020
Q4 		$31.4M Buy
133,036
+131,123
+6,854% +$30.1M 0.31% 91
2020
Q3 		$521K Buy
+1,913
New +$528K 0.01% 453

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return
AMF Tjänstepension
AMF Tjänstepension Stockholm, Sweden $17.2B AUM 28.3% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return
Montrusco Bolton Investments
Montrusco Bolton Investments Montreal, Quebec, Canada $5.77B AUM 24.61% 1-Year Est. Return
Birch Hill Investment Advisors
Birch Hill Investment Advisors Boston, Massachusetts $2.43B AUM 15.45% 1-Year Est. Return
Fjarde Ap-fonden
Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return
Provident Investment Management
Provident Investment Management Novi, Michigan $999M AUM 19.45% 1-Year Est. Return
ABN AMRO Investment Solutions
ABN AMRO Investment Solutions Paris Cedex 008 $13.2B AUM 30.55% 1-Year Est. Return

Davenport & Co's VRTX Position: Q3 2026 in Review

Davenport & Co reduced its Vertex Pharmaceuticals (VRTX) stake by 2.1% in Q3 2026, selling an estimated $2.21M and leaving 202,800 shares worth $106M. The position accounts for 0.53% of the portfolio, ranked #56.

Davenport & Co first reported a position in VRTX in Q3 2020 and has held it in 25 quarters since. The position peaked at $110M in Q1 2025. 478 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

  • Davenport & Co held 202,800 shares of Vertex Pharmaceuticals worth $106M as of Q3 2026.
  • Davenport & Co sold 4,308 Vertex Pharmaceuticals shares in Q3 2026, an estimated $2.21M.
  • Vertex Pharmaceuticals made up 0.53% of Davenport & Co's portfolio in Q3 2026, its #56 holding.
  • Davenport & Co first reported a position in Vertex Pharmaceuticals in Q3 2020 and has held it in 25 quarters since.
  • Davenport & Co's Vertex Pharmaceuticals position peaked at $110M in Q1 2025.
  • 478 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Davenport & Co's 13F filing for Q3 2026, filed 14 Oct 2026.